Literature DB >> 27618216

Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease.

Chung-Han Hsieh1, Atossa Shaltouki1, Ashley E Gonzalez2, Alexandre Bettencourt da Cruz3, Lena F Burbulla4, Erica St Lawrence3, Birgitt Schüle5, Dimitri Krainc4, Theo D Palmer3, Xinnan Wang6.   

Abstract

Mitochondrial movements are tightly controlled to maintain energy homeostasis and prevent oxidative stress. Miro is an outer mitochondrial membrane protein that anchors mitochondria to microtubule motors and is removed to stop mitochondrial motility as an early step in the clearance of dysfunctional mitochondria. Here, using human induced pluripotent stem cell (iPSC)-derived neurons and other complementary models, we build on a previous connection of Parkinson's disease (PD)-linked PINK1 and Parkin to Miro by showing that a third PD-related protein, LRRK2, promotes Miro removal by forming a complex with Miro. Pathogenic LRRK2G2019S disrupts this function, delaying the arrest of damaged mitochondria and consequently slowing the initiation of mitophagy. Remarkably, partial reduction of Miro levels in LRRK2G2019S human neuron and Drosophila PD models rescues neurodegeneration. Miro degradation and mitochondrial motility are also impaired in sporadic PD patients. We reveal that prolonged retention of Miro, and the downstream consequences that ensue, may constitute a central component of PD pathogenesis. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27618216      PMCID: PMC5135570          DOI: 10.1016/j.stem.2016.08.002

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  46 in total

1.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.

Authors:  Daniela Berg; Katherine J Schweitzer; Petra Leitner; Alexander Zimprich; Peter Lichtner; Petra Belcredi; Theresa Brüssel; Claudia Schulte; Sylvia Maass; Thomas Nägele; Zbigniew K Wszolek; Thomas Gasser
Journal:  Brain       Date:  2005-12       Impact factor: 13.501

2.  Imaging axonal transport of mitochondria.

Authors:  Xinnan Wang; Thomas L Schwarz
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

3.  Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.

Authors:  Gaia Skibinski; Ken Nakamura; Mark R Cookson; Steven Finkbeiner
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

4.  What causes the death of dopaminergic neurons in Parkinson's disease?

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla; Joshua A Goldberg
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

5.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

Review 6.  Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.

Authors:  Maximilian Sloan; Javier Alegre-Abarrategui; Richard Wade-Martins
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

7.  G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.

Authors:  Tatiana D Papkovskaia; Kai-Yin Chau; Francisco Inesta-Vaquera; Dmitri B Papkovsky; Daniel G Healy; Koji Nishio; James Staddon; Michael R Duchen; John Hardy; Anthony H V Schapira; J Mark Cooper
Journal:  Hum Mol Genet       Date:  2012-06-26       Impact factor: 6.150

8.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

9.  No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.

Authors:  Marta Garcia-Miralles; Janaky Coomaraswamy; Karina Häbig; Martin C Herzig; Natalja Funk; Frank Gillardon; Martina Maisel; Mathias Jucker; Thomas Gasser; Dagmar Galter; Saskia Biskup
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

10.  Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1.

Authors:  Yu-Chiang Lai; Chandana Kondapalli; Ronny Lehneck; James B Procter; Brian D Dill; Helen I Woodroof; Robert Gourlay; Mark Peggie; Thomas J Macartney; Olga Corti; Jean-Christophe Corvol; David G Campbell; Aymelt Itzen; Matthias Trost; Miratul Mk Muqit
Journal:  EMBO J       Date:  2015-10-15       Impact factor: 11.598

View more
  173 in total

1.  Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Authors:  Joanna A Korecka; Ria Thomas; Dan P Christensen; Anthony J Hinrich; Eliza J Ferrari; Simon A Levy; Michelle L Hastings; Penelope J Hallett; Ole Isacson
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo?

Authors:  Nadia Cummins; Jürgen Götz
Journal:  Cell Mol Life Sci       Date:  2017-10-30       Impact factor: 9.261

Review 3.  Mitochondrial dynamics and their potential as a therapeutic target.

Authors:  B N Whitley; E A Engelhart; S Hoppins
Journal:  Mitochondrion       Date:  2019-06-19       Impact factor: 4.160

Review 4.  Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases.

Authors:  Xinwen Zhang; Di Hu; Yutong Shang; Xin Qi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-03-18       Impact factor: 5.187

5.  Reintroduction of the archaic variant of NOVA1 in cortical organoids alters neurodevelopment.

Authors:  Cleber A Trujillo; Edward S Rice; Nathan K Schaefer; Isaac A Chaim; Emily C Wheeler; Assael A Madrigal; Justin Buchanan; Sebastian Preissl; Allen Wang; Priscilla D Negraes; Ryan A Szeto; Roberto H Herai; Alik Huseynov; Mariana S A Ferraz; Fernando S Borges; Alexandre H Kihara; Ashley Byrne; Maximillian Marin; Christopher Vollmers; Angela N Brooks; Jonathan D Lautz; Katerina Semendeferi; Beth Shapiro; Gene W Yeo; Stephen E P Smith; Richard E Green; Alysson R Muotri
Journal:  Science       Date:  2021-02-12       Impact factor: 47.728

Review 6.  Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells.

Authors:  Jenne Tran; Helena Anastacio; Cedric Bardy
Journal:  NPJ Parkinsons Dis       Date:  2020-04-24

Review 7.  Mitophagy in tumorigenesis and metastasis.

Authors:  Logan P Poole; Kay F Macleod
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 8.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 9.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 10.  Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.

Authors:  S L Sison; S C Vermilyea; M E Emborg; A D Ebert
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-04       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.